drugset / Trial / NCT02697838
Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric cancer which paclitaxel-resistant.
Timeline
- Start
- 2016-08-01
- Primary completion
- 2018-03-31
- Completion
- 2018-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 850 mg | Oral |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |
| Background | Levoleucovorin | Unknown | 200 mg/m2 | — |